UNASSIGNED: We design a single-arm, open-label, prospective study to evaluate the efficacy and safety of combination therapy with everolimus and TAE in patients with liver metastases of GEP-NETs. The study started in June 2021 at Okayama University Hospital and is expected to enroll 18 patients over a 2-year period.
UNASSIGNED: This study is a prospective study investigating a new treatment method for a rare disease called GEP-NETs. We may obtain useful information that contributes to the treatment guidelines in this study. However, NET is a rare disease, and although the number of cases is statistically established, it may not be possible to accurately assess causality.TRIAL REGISTRATION NUMBER: jRCT1061210015.
UNASSIGNED:我们设计了一个单臂,开放标签,前瞻性研究评估依维莫司和TAE联合治疗GEP-NETs肝转移患者的疗效和安全性。该研究于2021年6月在冈山大学医院开始,预计将在2年内招募18名患者。
UNASSIGNED:这项研究是一项前瞻性研究,旨在研究一种称为GEP-NETs的罕见疾病的新治疗方法。我们可能会获得有助于本研究治疗指南的有用信息。然而,NET是一种罕见的疾病,尽管病例数量是统计确定的,可能无法准确评估因果关系。试用登记号:jRCT1061210015。